| Issue Date | Title | Involved Person(s) |
| 14-Dec-2022 | Estimating risk of antidepressant withdrawal from a review of published data | Horowitz, Mark Abie; Framer, Adele; Hengartner, Michael P.; Sørensen, Anders; Taylor, David |
| 14-Feb-2022 | Opinion: Regulators are approving drugs without clear evidence that they work | Hengartner, Michael Pascal |
| 2022 | Suizidpräventive Effekte von Ketamin und Esketamin | Plöderl, Martin; Hengartner, Michael P.; Volkmann, Constantin |
| 17-Dec-2021 | Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise? | Plöderl, Martin; Hengartner, Michael Pascal |
| Dec-2021 | Evidence-biased antidepressant prescription : overmedicalisation, flawed research, and conflicts of interest | Hengartner, Michael P. |
| 8-Nov-2021 | Learning about the course of suicidal behavior but not about the effects of SSRIs | Plöderl, Martin; Hengartner, Michael Pascal |
| Mar-2021 | Antidepressiva – eine kritische Analyse der Verschreibungspraxis und Wirksamkeit | Hengartner, Michael Pascal |
| 2021 | Suicidality and other severe psychiatric events with duloxetine : re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia | Hengartner, Michael Pascal; Plöderl, Martin |
| 2021 | Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression | Hengartner, Michael Pascal; Plöderl, Martin |
| 2021 | Beneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder : a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses | Juul, Sophie; Siddiqui, Faiza; Barbateskovic, Marija; Jørgensen, Caroline Kamp; Hengartner, Michael Pascal, et al |
| 2021 | Prophylactic effects or withdrawal reactions? : an analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA | Hengartner, Michael Pascal; Plöderl, Martin |
| 2021 | Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder : a protocol for a systematic review with meta-analysis and Trial Sequential Analysis | Jørgensen, Caroline Kamp; Juul, Sophie; Siddiqui, Faiza; Barbateskovic, Marija; Munkholm, Klaus, et al |
| 2021 | Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies | Hengartner, Michael Pascal; Amendola, Simone; Kaminski, Jakob A.; Kindler, Simone; Bschor, Tom, et al |
| 2021 | Latrogenic effects of the FDA black box warning on antidepressants – signal or noise? | Plöderl, Martin; Hengartner, Michael P. |
| 2021 | Maintenance therapy with antidepressants : prophylactic effects or withdrawal reactions? | Plöderl, Martin; Hengartner, Michael P. |
